Autologous stem cell transplantation versus conventional chemotherapy: randomized studies.
| Author . | N . | Event-free survival . | Overall survival . |
|---|---|---|---|
| Abbreviations: NS, not significant. | |||
| Attal et al1 | 200 | 7-year: 16% vs 8% (P < .01) | 7-year: 43% vs 27% (P < .03) |
| Child et al2 | 401 | Median: 32 mo vs 20 mo (P < .01) | Median: 54 mo vs 42 mo (P < .01) |
| Palumbo et al3 | 194 | 3-year: 37% vs 16% (P < .001) | 3-year: 77% vs 62% (P < .01) |
| Fermand et al4 | 190 | Median: 25 mo vs 19 mo (NS) | Median : 47 mo vs 48 mo (NS) |
| Blade et al5 | 216 | Median: 42 mo vs 33 mo (NS) | Median: 66 mo vs 61 mo (NS) |
| Barlogie et al6 | 516 | 7-year: 16% vs 17% (NS) | 7-year: 37% vs 42% (NS) |
| Author . | N . | Event-free survival . | Overall survival . |
|---|---|---|---|
| Abbreviations: NS, not significant. | |||
| Attal et al1 | 200 | 7-year: 16% vs 8% (P < .01) | 7-year: 43% vs 27% (P < .03) |
| Child et al2 | 401 | Median: 32 mo vs 20 mo (P < .01) | Median: 54 mo vs 42 mo (P < .01) |
| Palumbo et al3 | 194 | 3-year: 37% vs 16% (P < .001) | 3-year: 77% vs 62% (P < .01) |
| Fermand et al4 | 190 | Median: 25 mo vs 19 mo (NS) | Median : 47 mo vs 48 mo (NS) |
| Blade et al5 | 216 | Median: 42 mo vs 33 mo (NS) | Median: 66 mo vs 61 mo (NS) |
| Barlogie et al6 | 516 | 7-year: 16% vs 17% (NS) | 7-year: 37% vs 42% (NS) |